222 related articles for article (PubMed ID: 23631463)
1. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
Vasiljevik T; Franks LN; Ford BM; Douglas JT; Prather PL; Fantegrossi WE; Prisinzano TE
J Med Chem; 2013 Jun; 56(11):4537-50. PubMed ID: 23631463
[TBL] [Abstract][Full Text] [Related]
2. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
[TBL] [Abstract][Full Text] [Related]
3. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
4. New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.
Nimczick M; Decker M
ChemMedChem; 2015 May; 10(5):773-86. PubMed ID: 25820617
[TBL] [Abstract][Full Text] [Related]
5. Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor.
Han S; Chen JJ; Chen JZ
Mini Rev Med Chem; 2014 May; 14(5):426-43. PubMed ID: 24766386
[TBL] [Abstract][Full Text] [Related]
6. Xie2-64, a novel CB
Jordan CJ; Feng ZW; Galaj E; Bi GH; Xue Y; Liang Y; McGuire T; Xie XQ; Xi ZX
Neuropharmacology; 2020 Oct; 176():108241. PubMed ID: 32712273
[TBL] [Abstract][Full Text] [Related]
7. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
8. Alcohol-induced conditioned place preference is modulated by CB2 cannabinoid receptors and modifies levels of endocannabinoids in the mesocorticolimbic system.
Martín-Sánchez A; Warnault V; Montagud-Romero S; Pastor A; Mondragón N; De La Torre R; Valverde O
Pharmacol Biochem Behav; 2019 Aug; 183():22-31. PubMed ID: 31220547
[TBL] [Abstract][Full Text] [Related]
9. Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.
Shi Y; Duan YH; Ji YY; Wang ZL; Wu YR; Gunosewoyo H; Xie XY; Chen JZ; Yang F; Li J; Tang J; Xie X; Yu LF
J Med Chem; 2017 Aug; 60(16):7067-7083. PubMed ID: 28726401
[TBL] [Abstract][Full Text] [Related]
10. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
Galaj E; Xi ZX
CNS Drugs; 2019 Oct; 33(10):1001-1030. PubMed ID: 31549358
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.
Ford BM; Franks LN; Radominska-Pandya A; Prather PL
PLoS One; 2016; 11(12):e0167240. PubMed ID: 27936172
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.
Franks LN; Ford BM; Madadi NR; Penthala NR; Crooks PA; Prather PL
Eur J Pharmacol; 2014 Aug; 737():140-8. PubMed ID: 24858620
[TBL] [Abstract][Full Text] [Related]
13. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
Rempel V; Volz N; Hinz S; Karcz T; Meliciani I; Nieger M; Wenzel W; Bräse S; Müller CE
J Med Chem; 2012 Sep; 55(18):7967-77. PubMed ID: 22916707
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB
Qian HY; Wang ZL; Chen LL; Pan YL; Xie XY; Xie X; Chen JZ
ChemMedChem; 2018 Nov; 13(22):2455-2463. PubMed ID: 30246417
[TBL] [Abstract][Full Text] [Related]
17. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.
Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB
Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
19. The Endocannabinoid System and Alcohol Dependence: Will Cannabinoid Receptor 2 Agonism be More Fruitful than Cannabinoid Receptor 1 Antagonism?
Oppong-Damoah A; Gannon BM; Murnane KS
CNS Neurol Disord Drug Targets; 2022; 21(1):3-13. PubMed ID: 33573565
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological regulation of cannabinoid CB2 receptor modulates the reinforcing and motivational actions of ethanol.
Navarrete F; García-Gutiérrez MS; Manzanares J
Biochem Pharmacol; 2018 Nov; 157():227-234. PubMed ID: 30063884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
